The Company:
XG (XGTI) Technology brands themselves as delivering cognitive radio network technology that helps to meet the world's rising demand for reliable and wireless broadband. Moreover their products help a wide variety of network operators make more efficient use of scarce radio spectrum assets. Recently, on October 7 2013, The Company was granted FCC certification that clears the way for the Company to begin shipping their xMax Access Point. This key hurdle that has been overcome can allow the company to begin production against their $35 million dollar backlog in an attempt to gain profitability - an event I do not think will buffer the Company's debt now or moving forward. As such dilution and more debt are likely, that can cause turmoil for the company moving forward.
IPO:
On July 18, 2013 XG Technology announced their initial public offering of 1,337,792 shares of common stock and warrants to purchase another 668,896 shares of common stock all with an initial public price of $5.50 per shares and $0.01 per warrant. The IPO raised around $8.5 million, higher than the expected $7,357,856 that the company was expecting, due to the excersize of an over allotment option of an addition 200k shares and 100k in warrants that can be transferred to an equal number of shares. Shares of the company are down 40% Post IPO already, to a price per share of $3.18 at the time of this article's writing.
Top Safest Stocks To Buy For 2016: Bellicum Pharmaceuticals Inc (BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company��s product pipeline includes clinical product candidates, such as BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates, including BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). The Company��s Chemical Induction of Dimerization (CID) technology platform engineers and controls components of the immune system in real time.
CaspaCIDe
CaspaCIDe is the Company��s Chemical Induction of Dimerization (CID) safety switch technology. The CaspaCIDe eliminates cells in the event of toxicity. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9 (iCasp9), an enzyme that is part of the apoptotic pathway. The infusion of rimiducid triggers activation of this domain of caspase-9, which in turn leads to selective apoptosis of the CaspaCIDe-containing cells. The CaspaCIDe technology is applied to its lead clinical product candidate, BPX-501 and to its TCR product candidate, BPX-701.
The CaspaCIDe technology has demonstrated clinical efficacy in human patients beginning as soon as 30 minutes after administration of the activating drug, rimiducid. In the preclinical studies, rimiducid reduced or eliminated CaspaCIDe-containing cells in a dosage dependent manner. The National Cancer Institute is conducting a Phase I/II clinical trial for sarcoma! and other solid tumors with a chimeric antigen receptor (CAR) construct targeting a solid tumor antigen combined with CaspaCIDe.
CIDeCAR
CIDeCAR Technology consists of a CAR T cell that incorporates its co-stimulatory domain, MC, for improved T-cell activation and proliferation, and the CaspaCIDe safety switch. CAR interaction with cancer cell antigens leads to MC signaling, which then leads to activation of T cells. In the event of serious toxicity, rimiducid activation of caspase-9 eliminates the CIDeCAR T cells.
The Company has conducted proof-of-principle preclinical studies for CIDeCAR technology, CIDeCAR candidate BPX-401 and CIDeCAR solid tumor CAR targeting Her2, in which, both were evaluated in vitro. These preclinical studies demonstrated that CIDeCAR technology results in enhanced activation, proliferation and tumor cell killing; and the elimination of these CIDeCAR T cells after exposure to rimiducid.
GoCAR-T
The Company��s GoCAR-T technology incorporates a switch that activates CAR T cells when triggered by both rimiducid and the targeted antigen expressed on the surface of the cancer cells. The GoCAR-T technology separates the CIDeCAR dual co-stimulatory domain, MC, from the antigen recognition domain and moves it onto a separate molecular switch that can be controlled by rimiducid. GoCAR-T cells can only be fully activated when exposed to both the cancer cells and rimiducid. This separation controls the degree of activation of the CAR T cells through adjustments to the amount of rimiducid administered, but still in a tumor-dependent manner.
The Company conducted a proof-of-principle in vitro study for GoCAR-T technology, in which it demonstrated that the GoCAR-T cells targeting the PSCA antigen can only be fully activated, as evidenced by production of IL-2 (left panel) and T-cell proliferation (right panel) when the GoCAR-T cells are exposed to both their target PSCA-expressing human pancreatic cancer cells ! and rimid! ucid. In further in vivo studies of GoCAR-T technology, target antigen PSCA-expressing Capan-1 human pancreatic tumors were established in immune-deficient, or NSG, mice. After seven days, five mice received control T cells modified only with firefly luciferase, an imaging protein, and 10 mice received T cells modified with MC in the form of a molecular switch or iMC, plus a PSCA. CAR (together, BPX-601) and firefly luciferase. Five mice in this second group also received 5 mg/kg rimiducid weekly. T-cell imaging clearly demonstrated that GoCAR-T cells can be stimulated to proliferate in vivo when exposed to target antigen-expressing cancer cells by rimiducid administration.
DeCIDe
The DeCIDe technology is used to control the activation of dendritic cells. The DeCIDe technology couples the signaling domains of CD40 and MyD88 to its CID binding domain, to create inducible MC switch, which is then insert into dendritic cells along with the PSMA antigen to take control of the activation of the dendritic cells and the resulting immune response to cancer. Upon exposure to rimiducid, DeCIDe-containing dendritic cells become highly activated. The DeCIDe technology activates dendritic cells with rimiducid after the patient has been vaccinated and the dendritic cells have migrated to the draining lymph nodes.
The cultured BPX-201 cells transduced with DeCIDe switch technology produce supra-normal levels of IL-12 in response to rimiducid. These data demonstrates that, in addition to the temporal control of dendritic cell activation that DeCIDe technology affords, once exposed to rimiducid, DeCIDe-containing dendritic cells become highly activated, which may lead to more potent anti-cancer activity in patients.
BPX-501
The Company��s CaspaCIDe product candidate BPX-501, is under development for the treatment of hematological diseases. BPX-501 is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation (HSCT), us! ing donor! stem cells. The BPX-501 eliminates donor T cells through the triggering of the CaspaCIDe safety switch upon emergence of Graft-versus-host disease (GvHD). The BPX-501 improves stem cell engraftment and accelerates immune system recovery, while providing for resolution of GvHD. The BPX-501 has a range of applications: an add-back of donor T cells administered to accelerate immune system recovery after allogeneic haplo-HSCT in which the T cells in the transplanted stem cells were depleted, and a donor T-cell infusion administered to prevent or treat relapse of underlying disease after allogeneic HSCT independent of donor match.
The product has undergone a 10-patient Phase I clinical trial with CaspaCIDe modified T cells. Four patients developed GvHD after donor T-cell infusion. A single dosage of rimiducid eliminated around 90% of the modified T cells and resolved GvHD in all four patients without recurrence of GvHD. In the second clinical trial of CaspaCIDe-modified T cells, these demonstrations have been replicated in preliminary data from three patients. BPX-501 is being evaluated in multiple Phase I/II clinical trials in the United States, which includes BP-001, a clinical trial in adults and and BP-003, a clinical trial in children. During the BP-001 clinical trial, BPX-501 is administered after initial allogeneic HSCT for hematological cancers. The BP-003 clinical trial in children with orphan inherited blood disorders includes the administration of BPX-501 after initial allogeneic HSCT. The Company also initiated an additional Phase I/II clinical trial, BPX-004 in children with hematological cancers or orphan inherited blood disorders.
BPX-201
The Company��s product candidate under development, BPX-201 is a dendritic cell cancer vaccine intended to treat metastatic castrate-resistant prostate cancer (mCRPC). BPX-201 is an autologous therapy, in which the patient��s own white blood cells are extracted and modified ex vivo. The cells are matured and then gen! etically ! engineered to express the DeCIDe switch domains and the prostate-specific membrane antigen (PSMA) antigen. The modified cells are then washed, apportioned into individual dosages, and frozen for later administration to the patient. The incorporation of the DeCIDe switch in the presence of rimiducid activates the therapy.
The Company is evaluating BPX-201 in an 18-patient Phase I clinical trial for mCRPC. It is evaluating opportunities for BPX-201 in combination with other cancer immunotherapies, such as checkpoint inhibitors.
BPX-701
The Company��s CaspaCIDe T cell receptor (TCR) Product Candidate, BPX-701 is under development for the treatment of Solid Tumors. BPX-701 is a TCR-based therapy for the treatment of PRAME-expressing melanoma, sarcomas and neuroblastomas. BPX-701 is designed to target preferentially-expressed antigen in melanoma (PRAMEa gene) that is predominantly expressed in human melanomas but not in normal tissues.
The BPX-701 has demonstrated complete elimination in response to rimiducid. The Clinical Cancer Research 2011 has demonstrated that PRAME-specific clones showed high reactivity against a panel of PRAME positive tumor cell lines, metastatic melanoma, sarcomas and neuroblastoma tissues, and no reactivity against normal cell types, with the exception of low reactivity against kidney epithelial cells and intermediate reactivity against mature dendritic cells. The vitro studies demonstrated BPX-701��s affinity to panels of cancer cells presenting PRAME peptides and low affinity to non-tumor cells. In other in vitro studies, rimiducid administration has proved the ability to eliminate BPX-701 cells.
BPX-401
The Company��s CIDeCAR Product Candidate under development, BPX-401, is developed for the treatment of Hematological Cancers, such as acute lymphotcytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and certain types of non-Hodgkin��s lymphoma. The CIDeCAR consists of CAR T cells modified to! include ! its CaspaCIDe safety switch and in which the CAR incorporates the signaling domains of two proteins, MyD88 and CD40. These proteins form the Company��s dual co-stimulatory domain, MC, which is designed to activate T cells in the presence of cancer cells. The Company has generated preclinical proof-of-principle data in vitro signifying that BPX-401 has CAR T cell activation and proliferation potential, and may be effective in killing cancer cells.
BPX-601
The Company��s GoCAR-T Product Candidate, BPX-601, is proposed for the treatment of Solid Tumors. The BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the prostate stem cell antigen (PSCA), such as some prostate, pancreatic, bladder, esophageal and gastric cancers. The Company��s GoCAR-T technology consists of CAR and T cells. GoCAR-T controls activation and proliferation of the CAR T cells through the scheduled administration of a course of rimiducid infusions.
BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the PSCA antigen. The Company has demonstrated positive proof-of-principle data in an animal pancreatic tumor model.
The Company competes with Adaptimmune Limited, bluebird bio, Inc., Celgene Corporation, Cellectis SA, GlaxoSmithKline plc, Intrexon Corporation, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis AG and Pfizer Inc.
Advisors' Opinion:- [By John Udovich]
Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) �� meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.
Hot Shipping Companies To Own In Right Now: RELM Wireless Corp (RWC)
RELM Wireless Corporation (RELM) provides two-way radio communications equipment. RELM designs, manufactures and markets wireless communications products consisting of two-way land mobile radios, repeaters, base stations, and related components and subsystems. Two-way land mobile radios can be units that are hand-held (portable) or installed in vehicles (mobile). The Company's P-25 digital products and the Company's analog products function in the VHF (136 megahertz - 174 megahertz), UHF (380 megahertz - 470 megahertz, 450 megahertz - 520 megahertz) and 700-800 megahertz bands. The Company offers products under two brand names: BK Radio and RELM. BK Radio-branded products serve the government and public safety market and RELM-branded products serve the business and industrial market.
BK Radio-branded products consist of land-mobile radio equipment for professional radio users primarily in government and public safety applications. RELM's P-25 digital products are marketed under the BK Radio brand. RELM-branded products provide two-way communications for commercial and industrial concerns, such as hotels, construction firms, schools, and transportation services. The Company provides products to a range of customers, including emergency, public safety, homeland security and military customers of federal and state government agencies, as well as various commercial enterprises. The Company's two-way radio products are used in harsh and hazardous conditions.
The Company competes with Motorola Solutions, Inc.
Advisors' Opinion:- [By Roberto Pedone]
Relm Wireless (RWC) is engaged in the designing, manufacturing and marketing wireless communications products consisting of two-way land mobile radios, repeaters, base stations and related components and subsystems. This stock closed up 2.8% to $3.58 in Tuesday's trading session.
Tuesday's Range: $3.40-$3.58
52-Week Range: $1.42-$3.74
Tuesday's Volume: 106,000
Three-Month Average Volume: 74,659From a technical perspective, RWC trended higher here right above some near-term support levels at $3.20 to $3.10 with above-average volume. This stock has been uptrending for the last two months, with shares moving higher from its low of $2.62 to its intraday high of $3.58. During that move, shares of RWC have been making mostly higher lows and higher highs, which is bullish technical price action. That move is quickly pushing shares of RWC within range of triggering a major breakout trade. That trade will hit if RWC manages to take out its 52-week high at $3.74 with high volume.
Traders should now look for long-biased trades in RWC as long as it's trending above some near-term support levels at $3.20 or its 50-day at $3.10 and then once it sustains a move or close above $3.74 with volume that hits near or above 74,659 shares. If that breakout hits soon, then RWC will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $4.50 to $5.
Hot Shipping Companies To Own In Right Now: Grupo Casa Saba S.A. de C.V.(SAB)
Grupo Casa Saba, S.A.B. de C.V., through its subsidiaries, operates as a multi-channel and multi-product wholesale distributor primarily in Mexico. It distributes pharmaceutical products; health and beauty aids; publication products, such as magazines, books, albums, and stickers; food and non-perishable products; personal care and consumer goods; and general merchandise. The company also sells pharmaceutical products through its Farmacias ABC pharmacy chain located in Guadalajara, Jalisco; Farmacias Provee de Especialidades primarily located in Monterrey and Nuevo Leon of Mexico, as well as in the states of Chihuahua and Coahuila; and through Farmacias Benavides. In addition, it provides freight services to third parties. Further, it operates medical clinics; and offers specialized medical, rehabilitation, and surgical services, as well as provides real estate services. The company serves pharmacies, mass merchandisers, retail and convenience stores, specialty stores, sup ermarkets, and other specialized channels. As of December 31, 2010, it operated a distribution network consisting of 22 active distribution centers. It also operates in Brazil, Chile, and Peru. Grupo Casa Saba, S.A.B. de C.V. was founded in 1892 and is based in Mexico, Mexico.
Advisors' Opinion:- [By Dividend Mantra]
Altria Group, Inc. operates as a holding company with a number of subsidiaries, including Philip Morris USA Inc., U.S. Smokeless Tobacco Company LLC, John Middleton Co., Ste. Michelle Wine Estates Ltd. and Philip Morris Capital Corporation. They also hold approximately 26.9% of the economic and voting rights of SABMiller plc (SAB).
Hot Shipping Companies To Own In Right Now: Himax Technologies Inc.(HIMX)
Himax Technologies, Inc., together with its subsidiaries, designs, develops, and markets semiconductors for flat panel displays. Its products include display drivers and timing controllers for various thin film transistor liquid crystal displays (TFT-LCD) panels, which are used in desktop monitors, notebook computers, televisions, and mobile handsets, as well as consumer electronics products comprising netbook computers, digital cameras, mobile gaming devices, portable DVD players, digital photo frame, and car navigation displays; and TFT-LCD television and monitor semiconductor solutions. The company also provides liquid crystal on silicon (LCOS) products for palm-size mobile projectors; power management integrated circuits, which include drivers, amplifiers, DC to DC converters and other semiconductors; complementary metal oxide semiconductor image sensors for camera-equipped mobile devices, such as mobile phones and notebook computers with a focus on lowlight image and video quality; and wafer level optics products. It serves TFT-LCD panel manufacturers, mobile device module manufacturers, and television makers. Himax Technologies, Inc. was founded in 2001 and is headquartered in Tainan, Taiwan.
Advisors' Opinion:- [By Roberto Pedone]
Himax Technologies (HIMX), a fabless semiconductor company, provides display imaging processing technologies to consumer electronics worldwide. This stock closed up 5.2% to $9.02 in Tuesday's trading session.
Tuesday's Range: $8.40-$9.05
52-Week Range: $5.70-$16.15
Tuesday's Volume: 5.88 million
Three-Month Average Volume: 4.83 millionFrom a technical perspective, HIMX ripped sharply higher here right above some near-term support at $8.26 with above-average volume. This jump to the upside on Tuesday is quickly pushing shares of HIMX within range of triggering a big breakout trade. That trade will hit if HIMX manages to take out Tuesday's intraday high of $9.05 to more near-term resistance at $9.57 and then above its 200-day moving average of $9.66 with high volume.
Traders should now look for long-biased trades in HIMX as long as it's trending above that key near-term support at $8.26 and then once it sustains a move or close above those breakout levels with volume that hits near or above 4.83 million shares. If that breakout hits soon, then HIMX will set up to re-test or possibly take out its next major overhead resistance levels at $11.18 to $11.69.
- [By mitu77]
Himax Technologies(HIMX) is gradually and relentlessly turning around after a woeful time in the recent past. Himax is seeing growth in every last bit of its product sections, including little and medium driver ICs, large board driver ICs, and non-driver ICs. One of the factors for the organization's development is solid interest from its Korean end client. The organization as of late was downsized by Bank of America. The liquid crystal on silicon (LCoS) business of the organization, which was mostly reliant on Google Glass project, influenced the Bank��s update as the Google Glass launch was deferred. Anyhow investors ought to be hopeful about Himax's development as its products are ingredients of various gadgets & devices that are in high demand. In a long run, such updates (Bank of America pertinent to Google Glass) should not make a big deal in performance of the company.
- [By jaggom]
Himax Technologies (HIMX) has touched new highs and was trading impressively on the stock market as a result of news that it will be supplying LCOS micro displays to Google. But the stock had run ahead of its fundamentals, and investors were buying more shares under the belief that Google Glass will lead Himax to new highs. Despite a slowdown in revenue and a string of bad quarterly results, Himax shares shone. But the scene has changed now.
Hot Shipping Companies To Own In Right Now: Oi SA (OIBR)
Oi S.A., formerly Brasil Telecom S.A., incorporated on November 27, 1963, is a telecommunication service provider in Region II in Brazil. The Company offers a range of integrated telecommunication services that includes fixed-line and mobile telecommunication services, data transmission services (including broadband access services), Internet service provider (ISP) services and other services, for residential customers, small, medium and large companies, and governmental agencies. The Company provides services, which include Fixed-Line Telecommunications Services and Data Transmission Services, Mobile Telecommunications Services and other services.
Local Fixed-Line Services
As of December 31, 2010, the Company had approximately 7.2 million local fixed-line customers in Region II. Local fixed-line services include installation, monthly subscription, metered services, collect calls and supplemental local services. Metered services include local calls that originate and terminate within a single local area. ANATEL has divided Region II into 1,772 local areas. Local fixed-line services also include in-dialing services (direct transmission of external calls to extensions) for corporate clients. For corporate clients in need of lines, the Company offers digital trunk services, which optimize and increase the speed of the customer��s telephone system.
Long-Distance Services
The long distance services include fixed line-to-fixed line and mobile long distance services. It provides domestic long-distance services for calls originating from Region II through interconnection agreements, mainly with Telemar in Region I and Telecomunicavoes de Sao Paulo S.A. (Telesp), in Region III permit the Company to interconnect directly with their local fixed-line networks, and through its network facilities in Sao Paulo, Rio de Janeiro and Belo Horizonte. It provides international long-distance services originating from Region II through agreements to interconnect its netw! ork with those of the main telecommunication service providers worldwide. It provides mobile long-distance services originating from Region II through interconnection agreements, with Telemar in Region I, Telesp in Region III, and each of the principal mobile services providers operating in Brazil that permit it to interconnect directly with their local fixed-line and mobile networks. It provides international long-distance services originating or terminating on its customer��s mobile handsets through agreements to interconnect its network with those of the main telecommunication service providers worldwide.
Mobile Telecommunication Services
As of December 31, 2010, the Company had approximately 7.8 million subscribers located in 1,281 municipalities in Region II. As of December 31, 2010, 87.5% of the Company��s customers subscribed to pre-paid plans and 12.5% subscribed to post-paid plans. The Company markets Oi Ligador subscriptions to its pre-paid customers, which allow these customers to receive bonus minutes with each purchase of additional credits. It charges a nominal subscription fee to enroll a customer in the Oi Ligador program and provide bonus minutes to these customers that may be used for local calls to its fixed-line or mobile subscribers, long-distance calls to its fixed-line subscribers, and sending Short Message Service (SMS, messages to mobile subscribers of any Brazilian mobile service provider.
The Company has roaming agreements with TNL PCS S.A., a wholly owned subsidiary of Telemar which provides mobile services and which it refers to as Oi, Companhia de Telecomunicacoes do Brasil Central (CTBC), and Sercomtel S.A. Telecomunicacoes (Sercomtel), providing its customers with automatic access to roaming services when traveling outside of Region II in areas of Brazil where mobile telecommunication services are available on the GSM standard. As of December 31, 2010, it had launched third generation (3G) services in a total of 84 municipalities, ! including! the nine state capitals in Region II and the Federal District. As of December 31, 2010, it had approximately 175,200 3G mobile broadband customers.
Data Transmission Services
The Company provides Internet access services using ADSL technology, which it refers as broadband services, to residential customers and businesses in the primary cities in Region II under the brand name Oi Velox. As of December 31, 2010, the Company offered broadband services in 1,810 municipalities in Region II and it had 1.9 million ADSL customers. Its network supports ADSL2+, VDSL2 and FTTx technologies. ADSL2+ is a data communications technology that allows data transmission at speeds of up to 24 megabits per second downstream and 1 megabits per second upstream. ADSL2+ permits offer a range of services than ADSL, including Internet protocol television (IPTV). As of December 31, 2010, approximately 50% of its fixed-line network had been updated to support ADSL2+. Very-high-bitrate digital subscriber line (VDSL2), is a DSL technology providing faster data transmission, up to 100 megabits per second upstream (downstream and upstream). Fiber to the x (FTTx), is a broadband network architecture that uses optical fiber to replace all or part of the usual metal local loop used for last mile telecommunications.
The Company provides a range of data transmission services through various technologies and means of access. Its commercial data transmission services include Industrial Exploitation of Dedicated Lines (Exploracao Industrial de Linha Dedicada (EILD)), under which it leases trunk lines to other telecommunication services providers, primarily mobile services providers, which use these trunk lines to link their radio base stations to their switching centers; Dedicated Line Services (Servicos de Linhas Dedicadas (SLD)), under which it leases dedicated lines to other telecommunication services providers, Internet service providers (ISPs) and corporate customers for use in private networks that! link dif! ferent corporate Websites; Internet Protocol (IP) services, which consist of dedicated private lines and dial-up Internet access, which it provides to the ISPs in Brazil, as well as Virtual Private Network (VPN), services that enable its customers to operate private Intranet and extranet networks, and frame relay services, which the Company provides to its corporate customers to allow them to transmit data using protocols based on direct use of its transmission lines, enabling the creation of VPNs.
The Company provides these data transmission services using its service network platform in Region II and its nationwide fiber optic cable network and microwave links. In addition, it provides services at the six cyber data centers located in Brasilia, Sao Paulo, Curitiba, Porto Alegre and Fortaleza. It provides hosting, collocation and information technology (IT) outsourcing at these centers, permitting its customers to outsource their IT structures to it or to use these centers to provide backup for their IT systems. It also owns and operates a submarine fiber optic network, which connects Brazil with the United States, Bermuda, Venezuela and Colombia. Through this network, it offers international data transportation services, primarily leased lines to other telecommunication services providers.
Network Usage Services (Interconnection Service)
The Company is authorized to charge for the use of its local fixed-line network on a per-minute basis for all calls terminated on its local fixed-line network in Region II that originate on the networks of other local fixed-line, mobile and long-distance service providers, and all long-distance calls originated on its local fixed-line network in Region II that are carried by other long-distance service providers. In addition, the Company charges network usage fees to long-distance service providers and operators of trunking services that connect switching stations to its local fixed-line networks.
Traffic Transporta! tion Serv! ices
The Company offers a long-distance usage service, called national transportation, under which it provides discounts to its long-distance network usage fees based on the volume of traffic and geographic distribution of calls generated by a long-distance or mobile services provider. The Company also offers international telecommunication service providers the option to terminate their Brazilian inbound traffic through its network, as an alternative to Embratel and Intelig Telecomunicacoes Ltda. (Intelig). The Company charges international telecommunication service providers a per-minute rate, based on whether a call terminates on a fixed-line or mobile telephone and the location of the local area in which the call terminates.
Public Telephone Services
The Company owns and operates public telephones throughout Region II. As of December 31, 2010, the Company had approximately 266,100 public telephones in service, which are operated by pre-paid cards.
Value-Added Services
Value-added services include voice, text and data applications, including voicemail, caller identification (ID), and other services, such as personalization (video downloads, games, ring tones and wallpaper), short message service (SMS)subscription services (horoscope, soccer teams and love match), chat, mobile television, location-based services and applications (mobile banking, mobile search, email and instant messaging). The Company also provides advanced voice services to its corporate customers, mainly 0800 (toll free) services, as well as voice portals where customers can participate in real-time chats and other interactive voice services. The Company also operates an Internet portal under the brand name iG.
The Company competes with Empresa Brasileira de Telecomunicacoes, GVT S.A., Vivo Participacoes S.A., Telecom Americas Group, TIM Participacoes S.A., Telesp and Intelig.
Advisors' Opinion:- [By alicet236]
Oi SA (OIBR) Reached the Five-Year Low of $1.63
The prices of Oi SA (OIBR) shares have declined to close to the five-year low of $1.63, which is 87.6% off the five-year high of $11.48. Oi SA is owned by three Gurus we are tracking. Among them, zero have added to their positions during the past quarter. 3 reduced their positions. Oi SA is a telecommunication service providing company in Brazil. Oi Sa has a market cap of $2.67 billion; its shares were traded at around $1.63 with a P/E ratio of 4.50 and P/S ratio of 0.14. The dividend yield of Oi Sa stocks is 23.36%. Oi Sa had an annual average earnings growth of 10.00% over the past 10 years.
- [By Roberto Pedone]
Oi (OIBR) provides integrated telecommunication services for residential customers, companies and governmental agencies in Brazil. This stock closed up 2.5% to 85 cents per share in Thursday's trading session.
Thursday's Range: $0.82-$0.86
52-Week Range: $0.76-$2.34
Thursday's Volume: 22.83 million
Three-Month Average Volume: 14.72 millionFrom a technical perspective, OIBR jumped modestly higher here right above some near-term support at 80 cents per share with heavy upside volume. This stock has been downtrending badly for the last five months, with shares sliding lower from its high of $1.97 to its recent 52-week low of 76 cents per share. During that downtrend, shares of OBIR have been making mostly lower highs and lower lows, which is bearish technical price action. That said, shares of OIBR now look ready to rebound and potentially trigger a near-term breakout trade. That trade will hit if OIBR manages to take out Thursday's intraday high of 86 cents to more near-term overhead resistance at 90 cents per share with high volume.
Traders should now look for long-biased trades in OIBR as long as it's trending above some key near-term support levels at 80 cents to 76 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 14.72 million shares. If that breakout triggers soon, then OIBR will set up to re-test or possibly take out its next major overhead resistance levels at $1.02 to $1.08 a share. Any high-volume move above those levels will then give OIBR a chance to tag its 50-day moving average of $1.18 to more resistance at $1.27.
- [By Roberto Pedone]
Oi (OIBR), through its subsidiaries, provides integrated telecommunication services for residential customers, companies and governmental agencies in Brazil. This stock closed up 8.6 % to $1.89 in Thursday's trading session.
Thursday's Range: $1.73-$1.91
52-Week Range: $1.44-$4.69
Thursday's Volume: 5.48 million
Three-Month Average Volume: 3.91 millionFrom a technical perspective, OIBR bounced sharply higher here back above its 50-day moving average of $1.83 with heavy upside volume. This move is quickly pushing shares of OIBR within range of triggering a near-term breakout trade. That trade will hit if OIBR manages to take out some near-term overhead resistance levels at $1.94 to $2.29 with high volume.
Traders should now look for long-biased trades in OIBR as long as it's trending above its 50-day at $1.83 or above more key near-term support at $1.72 and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.91 million shares. If that breakout triggers soon, then OIBR will set up to re-test or possibly take out its next major overhead resistance levels at $2.44 to its 200-day at $3.06.
Hot Shipping Companies To Own In Right Now: National Fuel Gas Company(NFG)
National Fuel Gas Company, through its subsidiaries, operates as a diversified energy company primarily in the United States. The company operates through four segments: Utility, Pipeline and Storage, Exploration and Production, and Energy Marketing. The Utility segment sells natural gas or provides natural gas transportation services to approximately 727,000 customers in Buffalo, Niagara Falls, and Jamestown, New York; and Erie and Sharon, Pennsylvania. The Pipeline and Storage segment provides interstate natural gas transportation and storage services for affiliated and nonaffiliated companies through an integrated gas pipeline system; and 27 underground natural gas storage fields, as well as 4 other underground natural gas storage fields owned and operated jointly with other interstate gas pipeline companies. This segment also transports natural gas for industrial customers and power producers in New York State. It owns the Empire Pipeline, a 157-mile pipeline; and the Empire Connector, which is a 76-mile pipeline extension. The Exploration and Production segment engages in the exploration for, and the development and purchase of natural gas and oil reserves in California, in the Appalachian region of the United States, and in the Gulf Coast region of Texas and Louisiana. As of September 30, 2009, this segment had proved developed and undeveloped reserves of 46,587 thousand barrels of oil and 248,954 million cubic feet equivalent of natural gas. The Energy Marketing segment markets natural gas to industrial, wholesale, commercial, public authority, and residential customers primarily in western and central New York and northwestern Pennsylvania. The company also develops and operates mid-range independent power production and landfill gas electric generation facilities. National Fuel Gas Company was founded in 1902 and is based in Williamsville, New York.
Advisors' Opinion:- [By Garrett Cook]
Utilities shares dropped by 0.04 percent in the US market on Wednesday. Top losers in the sector included National Fuel Gas Company (NYSE: NFG), down 1.1 percent, and Atmos Energy (NYSE: ATO), off 0.7 percent.
- [By Canadian Value]
- National Fuel Gas (NFG) for its great land position in the Marcellus shale play. He expects NFG to spin out its utility division and maybe do a joint venture on its big land position.
- [By Eric Volkman]
National Fuel Gas (NYSE: NFG ) is hewing tightly to tradition with its upcoming shareholder payout. The company has declared a bump in its quarterly dividend, to $0.375 per share. This will be dispensed on July 15 to shareholders of record as of June 28. That amount is 2.7% higher than the firm's previous four distributions of $0.365 apiece, the most recent of which was paid in April. Prior to that, National Fuel Gas handed out $0.355 per share.
- [By Jake L'Ecuyer]
Utilities sector was the leading decliner in the US market today. Among the sector stocks, Companhia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS) was down more than 5.3 percent, while National Fuel Gas Company (NYSE: NFG) tumbled around 2.8 percent.
Hot Shipping Companies To Own In Right Now: Spectral Diagnostics Inc (DIAGF)
Spectral Diagnostics Inc. (Spectral), incorporated on July 29, 1991, focuses on the development and commercialization, in North America, treatment for severe sepsis and septic shock. The Company also manufactures and sells certain reagents. Its products include Rapid Diagnostics for Sepsis, Endotoxin Activity Assay (EAA) and Toraymyxin. As of December 31, 2011, Spectral��s EAA endotoxin measurement was the only the United Sates Food and Drug Administration (FDA) cleared diagnostic on the market. Spectral Diagnostics (US) Inc. and Spectral Diagnostics (New Brunswick) Inc. are its subsidiaries.
The Company has developed a rapid diagnostic test for detection of components of gram negative bacterial cell wall (endotoxin). The EAA instrument is manufactured under contract for use in the hospital setting. The Toraymyxin hemoperfusion device removes endotoxin from the bloodstream and is manufactured by Toray Industries Inc. of Japan. The product is sold in Japan and Europe and has been used over 80,000 patients worldwide. As of December 31, 2011, Spectral was conducting clinical trials for the purpose of seeking regulatory approval in the United States. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies. Royalty revenues are earned from these license arrangements based on a percentage of end user sales of Troponin I.
The Company competes with Eli Lilly, Agennix AG, AstraZeneca, Eisai, Gambro, InflammaGen Therapeutics, Fresenius and CytoSorbents.
Advisors' Opinion:- [By maarnio]
Spectral Diagnostics (DIAGF) develops and commercializes theranostic treatment for severe sepsis in North America.
Shares outstanding (March 31, 2014)
) reported on Thursday that it is now predicting demand for 5,580 new airplanes in China over the next 20 years.